Vertex Pharmaceuticals (Vertex Pharmaceuticals) Interest Expense : $-44 Mil (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Vertex Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vertex Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-44 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vertex Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ 956 Mil. Vertex Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -11 Mil. Vertex Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 was 90.19. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vertex Pharmaceuticals Interest Expense Historical Data

The historical data trend for Vertex Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Interest Expense Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-58.50

-58.20

-61.50

-54.80

-44.10

Vertex Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-11.60	-11.40	-11.20	-10.90	-10.60

Vertex Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44 Mil.

Vertex Pharmaceuticals (NAS:VRTX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vertex Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-11 Mil. Its Operating Income for the three months ended in Dec. 2023 was $956 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $725 Mil.

Vertex Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	956	/	-10.6
	=	90.19

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Vertex Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Vertex Pharmaceuticals (Vertex Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (NAS:VRTX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VX1:Germany VX1:Germany VX1:Germany VRTX34:Brazil VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Executives

Jeffrey M Leiden	director	15 N BEACH ROAD, HOBE SOUND FL 33455
Wagner Charles F Jr	officer: EVP & Chief Financial Officer	C/O MILLIPORE CORP, BILLERICA MA 01820
Reshma Kewalramani	director, officer: CEO & President	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Stuart A Arbuckle	officer: EVP, COO	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Amit Sachdev	officer: SVP, Public Policy,Gov Affairs	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
David Altshuler	officer: EVP, Global Research and CSO	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Carmen Bozic	officer: EVP and CMO	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Bruce I Sachs	director	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Sangeeta N. Bhatia	director	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Michel Lagarde	director	450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017
Atkinson Edward Morrow Iii	officer: EVP, Chief Technical Ops. Off.	C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Ourania Tatsis	officer: EVP, Chief Reg. & Quality Off.	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Kristen Ambrose	officer: SVP & Chief Accounting Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Bastiano Sanna	officer: EVP, Cell & Genetic Therapies	C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210